CC
TCRX icon

Checkpoint Capital’s TScan Therapeutics TCRX Stock Holding History

Checkpoint Capital’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,017,650
Closed -$2.78M – 14
2025
Q1 		$2.78M Buy
2,017,650
+261,663
+15% +$566K 1.53% 10
2024
Q4 		$5.34M Buy
1,755,987
+930,646
+113% +$4.22M 2.72% 9
2024
Q3 		$4.11M Buy
+825,341
New +$4.98M 2.04% 9

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Checkpoint Capital's TCRX Position: Q2 2025 in Review

Checkpoint Capital sold out of TScan Therapeutics (TCRX) in Q2 2025, closing a stake of 2,017,650 shares — an estimated $2.78M sold.

Checkpoint Capital first reported a position in TCRX in Q3 2024 and held it in 3 quarters. The position peaked at $5.34M in Q4 2024. 81 funds tracked by Wall St. Rank hold TCRX as of Q2 2025.

  • Checkpoint Capital reported no remaining TScan Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Checkpoint Capital sold 2,017,650 TScan Therapeutics shares in Q2 2025, an estimated $2.78M.
  • Checkpoint Capital first reported a position in TScan Therapeutics in Q3 2024 and held it in 3 quarters.
  • Checkpoint Capital's TScan Therapeutics position peaked at $5.34M in Q4 2024.
  • 81 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2025.

Based on Checkpoint Capital's 13F filing for Q2 2025, filed 14 Aug 2025.